Moshe Lewis graduated from Mount Sinai Medical School in New York and fulfilled a residency training program in physical medicine and rehabilitation, at Tufts New England Medical Center in Boston where he served as chief resident. Moreover, he is a volunteer clinical faculty member at the University of California, San Francisco, and the Touro University College of Osteopathic Medicine. He currently serves as the Founder and CEO of the Golden Gate Institute For Integrative Medicine (GGIIM). He also coauthored a revolutionary new comprehensive, evidence-based book titled Understanding Pain: An Introduction for Patients and Caregivers (Rowman & Littlefield, 2015).

Geriatrics, Aging

Stephen Gethin-Jones has completed his Doctorate at the Unviersity of Cardiif in 2012 with a focus on homecare delivery to older housebound adults and he had continued to develop a specialist interest in home care and support services for older adults,with a particular focus on outcome focused care. He also has been involved in the development of services for community care in both the statutory and private sectors. He currently teach on a variety of health and social care degrees at both undergraduate and post graduate level.

Elder Care, Home Care

Dr Sylvia L.F. Pender is Associate Professor Reader in Mucosal Immunology, within Medicine at the University of Southampton. She is currently the Adjunct Associate Professor at International Medical University in Malaysia. She was a VC award winner in 2010 for promoting internationalization in the University. She is also a Global Partnership Award winner in 2013 for enhancing international research collaboration and partnership in Singapore, Malaysia and Hong Kong. She completed her BSc.(Hons), Biochemical Sciences at University of Keele 1992 and PhD, University of London 1996 (with an Overseas Research Scholarship award). She is a Research Fellow at St Bartholomew’s and the Royal London School of Medicine and Dentistry, University of London (1995). She acts as Non-clinical Lecturer, University of Southampton (2000). Dr Sylvia L.F. Pender is a Senior Lecturer at University of Southampton during 2005.

Molecular Biology, Cell Biology, Biochemistry Methods, Immunology, Cancer Biology, Cell Culture, PCR, Signaling Pathways and Matrix Metalloproteinase.

A Biomedical Engineer with advanced degrees in Applied Physiology & Applied Clinical Trials. Mark facilitates the translation of science, technology, & medicine for development & commercialization of medical technologies. Co-Founder, President, & CEO of PhenoMx, Inc.: focused on commercializing a Personalized Digital Physical Examination for Precision Medicine, Personalized Wellness, & Human Longevity. Founder, President, & CEO of Image Reading Center, Inc.: Imaging Core Laboratory & CRO developing Imaging Biomarkers for global multi-center Clinical Trials

Implementing & Standardizing Medical Imaging in a wide range of therapeutic areas.

Prof. Kai Ye has completed his PhD from Leiden University in the Netherlands and postdoctoral studies from European Bioinformatics Institute in UK. He was an assistant professor at Leiden University Medical Center and Washington University in St. Louis. He has published more than 50 papers in reputed journals with more than 20k citations.

Bioinformatics

Dr. Menolascino-Bel graduated from the University of Nebraska College of Medicine in 1983. She works in New York, NY and specializes in Psychiatry.

Psychiatrists diagnose and treat mental illness, such as depression, anxiety disorders, substance abuse, and schizophrenia. Most psychiatrists rely on a mix of medications and psychotherapy.

Samorodskaya I has completed her PhD at the age of 35 years from Smolensk Medical Institute. Previously, she worked as a cardiologist, researcher, taught students cardiology and the basics of evidence-based medicine, then worked as Chief doctor of Institute for coronary and vascular surgery A.N. Bakoulev National Scientific and Practical Center for Cardiovascular Surgery of the Ministry of Health RF (Moscow). Now she is Chief of Laboratory for demographic aspects of population’s health. National medical Center for Preventive Medicine under the Ministry of Health RF(Moscow). She has published more than 400 works in Russian journals and is a member of the editorial board.

Cardiovascular epidemology

Executive Director of PERSONAL, Precision and Personalized Oncology. Clinic and Molecular Laboratory of Genetics and Genomics dedicated to Cancer and Research President of GBOP: Brazilian Group of PRECISION ONCOLOGY

Precision Oncology

Howard Moskowitz, Harvard PhD in experimental psychology (1969) is founding partner and chief scientific officer of Mind Genomics Advisors. He has published extensively in many fields, using the science of Mind Genomics, which he invented more than 30 years ago. After a distinguished dual career in science and business, he changed course, creating an institute to help younger professionals as well as students and business, benefit from the application of Mind Genomics to practical problems in society, including commerce, health, education, and socal issues. Along with hundreds of scientific papers, he has written/edited 27 published books, with an additional 15 books finished but not yet published. His ‘oeuvre’ of work using Mind Genomics is available for download to interested parties at https://www.dropbox.com/sh/vlyiqp6p5eom0m1/AAC1WRPuHOGpax6TLq-md824a?dl=0

Genomics

Sergey Suchkov, MD, PhD was born in 11.01.1957, a researcher-immunologist, a clinician, graduated from Astrakhan State Medical University, Russia, in 1980.Suchkov has been trained at the Institute for Medical Enzymology, The USSR Academy of Medical Sciences,National Center for Immunology (Russia), NIH, Bethesda, USA) and British Society for Immunology to cover 4 British university facilities. Since 2005, Dr Suchkov has been working as Faculty Professor of I.M. Sechenov First Moscow State Medical University and Of A.I.Evdokimov Moscow State Medical & Dental University. From 2007, Suchkov is the First Vice-President and Dean of the School of PPPM Politics and Management of the University of World Politics and Law. In 1991-1995, Dr Suchkov was a Scientific Secretary-in-Chief of the Editorial Board of the International Journal“Biomedical Science” (Russian Academy of Sciences and Royal Society of Chemistry, UK) and The International Publishing Bureau at the Presidium of the Russian Academy of Sciences. In 1995-2005, Suchkov was a Director of the Russian-American Program in Immunology of the Eye Diseases.Dr Suchkov is a member of EPMA (European Association of Predictive, Preventive and Personalized Medicine,Brussels-Bonn), a member of the NY Academy of Sciences, a member of the Editorial Boards for Open Journal of Immunology and others. Dr Suchkov is known as an author of the Concept of post-infectious clinical and immunological syndrome, co-author of a concept of abzymes and their impact into the pathogenesis of autuimmunity conditions, and as one of the pioneers in promoting the Concept of PPPM into a practical branch of health services.

Predictive, Preventive and Personalized Medicine,Immunology, Medicine, Pathology

Sergey Zhuplatov is a Medical Director of the Metabolic Strategy and Development of AstraZeneca LP. Fort Washington, PA. He was graduated as MD at the Izhevsk State Medical Academy in Russia before finishing his fellowship in Internal Medicine/Endocrinology at Moscow Academy of Post diploma Education and Moscow Medical Institute of Transplantology in 1986. He accepted tenure and leading clinical consultant position in Endocrinology/Cardiology clinic at his Alma Mater ISMA. At this time, he started his Ph.D. dissertation in Cardiology with prevention of progressive CV events in Diabetes Mellitus Patients as the main topic, which was perfectly defended at Ural State Medical Academy on 1991. Dr. Zhuplatov has been working as an Assistant Professor and practicing physician till his emigration to the USA in 2002 as an exceptional ability person visa waiver. Before that he worked 2 years as a Medical Scientific Consultant for Merck S&D Co., and also as a Chief Medical Officer in Private Medical Clinic for 2 years. He published different works in Internal Medicine, Lipidology, Endocrinology, and Cardiology. He continued his scientific work in University of Utah Medical School till his merge to Pharmaceutical Industry in 2008. Since then he is working in Cardio/Metabolic area of Medical Affairs and Clinical Development of Bristol-Meyers Squibb and AstraZeneca Co. He currently resides in Bucks County PA with his wife Irina, Industrial Psychology Ph.D. They both like fine arts, travel, and reading. His two sons are graduate students in Economy and Medicine.

Diabetology,Lipids,Ischemic Heart Disease, Microcirculation,Echocardiography,Obesity.

Luigi Maselli received the Distinguished Doctor Award at San Raffaele University of Rome in honor of his significant contribution to Lifestyle Medicine in Italy. He is a neuroimmunologist with a PhD in Neurosciences and works as a Research Fellow at Sapienza University of Rome – School of Medicine and Dentistry and as a Visiting Fellow at Gabriele d’Annunzio University of Chieti-Pescara – School of Health Sciences. Dr. Maselli is the founding President of the Italian Lifestyle Medicine Association (ILMA). He is active in patient care, research, speaking, teaching and writing, and wrote the first Italian book on Lifestyle Medicine. After establishing his connection with the Institute of Lifestyle Medicine at Harvard Medical School, where he fell in love with Lifestyle Medicine, he established Lifestyle Medicine programs in several Italian universities. His overwhelming enthusiasm for life and propensity for helping others reflect the values that make Lifestyle Medicine unique- for the treatment and prevention of lifestyle-related chronic diseases.

Internal Medicine

Vincent S. Gallicchio has 42 years experience in academic medicine and research covering experimental hematology, immunology, and developmental therapeutics for human diseases such as AIDS and cancer. He has earned national and international respect and recognition for his efforts. In a first time study reporting on academic scholarly productivity in the Journal of Clinical Laboratory Science, Gallicchio was rated the number one academic biomedical laboratory science researcher in the United States. In addition to his passion for research, Gallicchio is equally passionate to teach, mentor and advise students. He has mentored many doctoral and post-doctoral students, dozens of master’s level students and hundreds of undergraduate students both foreign and domestic, many of whom are now esteemed researchers themselves at institutions such as: Oxford University, Eastern Kentucky University, University of Cincinnati, University of Florida, University of Kentucky, University of Limpopo (South Africa), Jewish and Mercy Hospitals in Cincinnati and major pharmaceutical companies such as Procter & Gamble and Johnson & Johnson. As a board certified medical laboratory scientist by the American Society of Clinical Pathology (ASCP), Gallicchio also serves as the Clinical Laboratory Director of the Lab Tree Clinical Biochemical Research Laboratory in Greenville, SC. He also serves as a consultant to Minerals Resources International, Inc on matters related to the health benefits of trace elements; and is a consulting Vice-President of Technology Development for Conversion Laboratories, LLC, and West Columbia, SC. He has served on the faculty and academic staff at the Yale University School of Medicine, the University of Kentucky Medical Center, the University of Central Lancashire (England) and the University of Wolver hampton (England). He has served as President of Alpha Eta Honor Society, the International Society for Lithium Research, International Federation of Biomedical Laboratory Science and currently serves as Vice President of the Educational and Research Centers in Trace Elements program operated under the auspice of UNESCO.

Personalized Medicine, cell science, Trace elemts, biology, Biomedical Laboratory.

Candida Fratazzi has worked in biomedical research for over 25 years. Prior to her full commitment to Boston Biotech Clinical Research, LLC, she served as Vice President of Clinical Research at MediVector, Inc. Dr. Fratazzi has also held management positions at Johnson & Johnson Pharmaceuticals, Altus Pharmaceuticals Inc., Shire HGT, and Vitex Inc. and Wyeth Pharmaceuticals. During her carrier, Dr. Fratazzi developed clinical strategies and plan developments for many drug candidates, presented in INDs and end-of-phase2 briefing documents. Furthermore, Dr. Fratazzi devoted a special attention to drug safety and risk management recognizing its critical value in the contest of clinical development. Her work resulted in the market approval of Tigecycline® IV (Wyeth), Velaglucerase alpha® (Shire), Replagal® in Canada, and submission of Lipoprotamase (Alnara).She is also chairman of Women in Bio of Greater Boston.

Personalized Medicine, Clinical research

Chakrabarty is currently a Distinguished University Professor in the Department of Microbiology and Immunology in the University of Illinois at Chicago College of Medicine. Apart from being an eminent scientist, Ananda Chakrabarty has been an advisor to judges, governments, and the UN.As one of the founding members of a United Nations Industrial Development Organization committee that proposed the establishment of the International Centre for Genetic Engineering and Biotechnology, he has been a member of its Council of Scientific Advisors ever since.He has served the U.S. government as a member of NIH Study Sections, a member of the Board on Biology of the National Academy of Science, and the Committee on Biotechnology of the National Research Council He has also served the Stockholm Environment Institute of Sweden. He has been on the scientific advisory boards of many academic institutions such as the Michigan Biotechnology Institute, the Montana State University Center for Biofilm Engineering, the Center for Microbial Ecology at the Michigan State University, and the Canadian Bacterial Diseases Network based in Calgary, Canada. Dr. Chakrabarty has also served as a member of the NATO Industrial Advisory Group based in Brussels, Belgium. He is a member of the board of directors of Einstein Institute for Science, Health and the Courts, where he participates in judicial education. More recently, he has been involved in international judicial work, serving as a Scientific Advisor for meetings in Hawaii and Ottawa, Canada, organized by the Supreme Court of Canada.

Cell Biology, Microbiology, Oncology,Biotechnology, Cancer cells

Hu is currently Senior Vice President and Head of Consulting in the US for the Pharmaceutical and Diagnostics industries at GlobalData Inc., a publicly listed global healthcare business intelligence and management consulting firm with a headquarter in London, UK. Earlier, aside from being the founding President of BioStrat Advisory LLC, for years he was the Managing Partner and Head of Bionest USA, both life science industry strategy consulting firms in the US. An early participant of the Human Genome Project and later involved in the International HapMap Project, Dr. Hu is now a recognized thought leader in the field of personalized / precision medicine (PM) business strategy, advising global pharmaceutical and diagnostics companies on how best to develop and commercialize personalized medicine drug and / or molecular diagnostics, and build internal business processes & capabilities for PM products. He currently serves on the Editorial Board of the peer-reviewed journal Personalized Medicine, in addition to several PM related industry consortia/committees. For example, he was the only representative from the management consulting industry invited to the US FDA Personalized Medicine Initiative, and co-organized / co-chaired a two-day conference / workshop on Personalized Medicine Strategic Decision Making onsite at the US FDA campus. He was also a Member of the BioNJ PM & Molecular Diagnostics Committee. He has been a frequently invited speaker on PM at conferences and to the leadership teams of many pharmaceutical companies, along with some notable business publications on this subject, including two (co) first authored papers in Nature Reviews, and such other journals as Supplement to Science and Personalized Medicine. As part of his extracurricular activities, he holds an Adjunct Professor position at the Chinese National Human Genome Center at Shanghai, Chinese Academy of Sciences, and Senior Advisor & Visiting Professor positions at the Beijing Genomics Institute.

Precision medicine, Personalized Medicine

Jon Burroughs, MD, MBA, FACHE, FAAPL is President and CEO of The Burroughs Healthcare Consulting Network, Inc. and works with some of the nation’s top healthcare consulting organizations to provide ‘best practice’ solutions and training to healthcare organizations throughout the country in the areas of governance, physician–hospital alignment strategies, as well as ways in which physicians and management can work together in new ways to solve quality, safety, operational, and financial challenges through the creation of population health programs and clinically integrated networks.

Dr. Burroughs serves on the national faculty of the American College of Healthcare Executives and the American Association for Physician Leadership, where he has been consistently rated as one of their top speakers and educators. He is the author of “Redesign the Medical Staff Model-A Collaborative Approach (published by Health Administration Press, January, 2015 which was honored with the 2016 James A. Hamilton Award for outstanding healthcare management book.

Vincent S. Gallicchio has 42 years experience in academic medicine and research covering experimental hematology, immunology, and developmental therapeutics for human diseases such as AIDS and cancer. He has earned national and international respect and recognition for his efforts. In a first time study reporting on academic scholarly productivity in the Journal of Clinical Laboratory Science, Gallicchio was rated the number one academic biomedical laboratory science researcher in the United States. In addition to his passion for research, Gallicchio is equally passionate to teach, mentor and advise students. He has mentored many doctoral and post-doctoral students, dozens of master’s level students and hundreds of undergraduate students both foreign and domestic, many of whom are now esteemed researchers themselves at institutions such as: Oxford University, Eastern Kentucky University, University of Cincinnati, University of Florida, University of Kentucky, University of Limpopo (South Africa), Jewish and Mercy Hospitals in Cincinnati and major pharmaceutical companies such as Procter & Gamble and Johnson & Johnson. As a board certified medical laboratory scientist by the American Society of Clinical Pathology (ASCP), Gallicchio also serves as the Clinical Laboratory Director of the Lab Tree Clinical Biochemical Research Laboratory in Greenville, SC. He also serves as a consultant to Minerals Resources International, Inc on matters related to the health benefits of trace elements; and is a consulting Vice-President of Technology Development for Conversion Laboratories, LLC, and West Columbia, SC. He has served on the faculty and academic staff at the Yale University School of Medicine, the University of Kentucky Medical Center, the University of Central Lancashire (England) and the University of Wolver hampton (England). He has served as President of Alpha Eta Honor Society, the International Society for Lithium Research, International Federation of Biomedical Laboratory Science and currently serves as Vice President of the Educational and Research Centers in Trace Elements program operated under the auspice of UNESCO.

Personalized Medicine, Cell Science, Trace Elements, Biology, Biomedical Laboratory

Sergey Suchkov, MD, PhD was born in 11.01.1957, a researcher-immunologist, a clinician, graduated from Astrakhan State Medical University, Russia, in 1980.Suchkov has been trained at the Institute for Medical Enzymology, The USSR Academy of Medical Sciences,National Center for Immunology (Russia), NIH, Bethesda, USA) and British Society for Immunology to cover 4 British university facilities. Since 2005, Dr Suchkov has been working as Faculty Professor of I.M. Sechenov First Moscow State Medical University and Of A.I.Evdokimov Moscow State Medical & Dental University. From 2007, Suchkov is the First Vice-President and Dean of the School of PPPM Politics and Management of the University of World Politics and Law. In 1991-1995, Dr Suchkov was a Scientific Secretary-in-Chief of the Editorial Board of the International Journal“Biomedical Science” (Russian Academy of Sciences and Royal Society of Chemistry, UK) and The International Publishing Bureau at the Presidium of the Russian Academy of Sciences. In 1995-2005, Suchkov was a Director of the Russian-American Program in Immunology of the Eye Diseases.Dr Suchkov is a member of EPMA (European Association of Predictive, Preventive and Personalized Medicine,Brussels-Bonn), a member of the NY Academy of Sciences, a member of the Editorial Boards for Open Journal of Immunology and others. Dr Suchkov is known as an author of the Concept of post-infectious clinical and immunological syndrome, co-author of a concept of abzymes and their impact into the pathogenesis of autuimmunity conditions, and as one of the pioneers in promoting the Concept of PPPM into a practical branch of health services

Predictive, Preventive and Personalized Medicine,Immunology, Medicine, Pathology

Anatoly Victorovich Skalny was born on the 12th of April, 1962 in Ivano-Frankovsk-City (Ukrain). Graduated school in Olyka village of Volynskaya oblast and medical faculty of Ivano-Frankovsk Medicine State Institute (1985) with honours. Began to carry aout scientific researches from 1979 in a student scientific society under the leadership of professor G.A. Babenko, a leading specialist in medicine elementology in Soviet Union. Ph.D. in Medicine (from 1990). Member of Council on trace elements in agriculture, biology and medicine in AS USSR and RAS (from 1987), Executive Committee of Moscow department of physicians-assistants' Society (from 1989), Boards in ecology and natural recources, science, culture and public health Political Consulting Council under the President of Russian Federation (from 1997), Member of advisory committee in ecology at Moscow City Parliament, co-founder of public movement "Healthy City - health of moscovites" (from 1998). In 1985–1991 worked as a research assistant, Junior Researcher and Researcher in department of restoration treatment of children with cerebral paralysis of Research Institute of common and justice psychiatry by V.P.Serbsky of HM USSR, department of alcoholism genetics in State Scientific Center of narcology of HM USSR. In 1988 he founded scientific-medical center "Element" that is the base to carry out researches of biosubstrates elemental content for medicine purposes during 11 years (for population, health and sanitary-hygienic organizations), scientific institutes such as Research Institute of pediatrics of RAMS, Center for perinatology, obstetrics and gynaecology of HM RF, Navy Institute of Hygiene of HM RF, colleges of medicine of Moscow, Ivanovo, Irkutsk, N.Novgorod and other cities. Center for Biotic Medicine, - autonomous non-profit organization (CBM), - was founded by A.V.Skalny in 1995 that is the unique scientific-methodical Center for problems of applied medicine elementology in RF and UIS. On the 19 of January, 2001 "Russian Society of Medicine Elementology" (RUSTEM) was founded to provide the strongest evolution of trace elements paradigm. During the period from 1982 about 200 scientific articles and thesis' were published by A.V.Skalny in special issues in Russia and abroad as well as manuals and mini-monographs in problems of practical medicine elementology. A.V. Skalny with co-authors registered 3 certificates of authorship and 3 patents of RF and Ukrain in the branch of producing new biologically active compounds of trace elements (Se, Zn) to treat and make prophylaxis of human diseases, methods of treatments of zinc deficiency states, alcohol coma and schysophrenia. To date new line in medicine and ecology, - medicine elementology, - is established by A.V. Skalny in Russia and UIS and developed successfully that studies peculiarities of human organism elemental composition in different functional states and disorders and the ways to increase organism adaptative functions with the help of trace elements metabolism correction. In SMC "Element" and CBM more than 20 Ph.D.'s and 5 D.Sc.' in medicine and biology were trained who develop different applied aspects of medicine elementology in branches of perinatology, endocrinology, urology, nephrology, labour medicine, nutrition hygiene, narcology in leaders clinics of Russia, Ukrain, Kazakhstan, Uzbekistan. In 1998-1999 production of new generation of effective major and trace elements' preparations (compounds with aspartic, spirulina) was organized under the methodic management of organizations headed by A.V. Skalny that awoke interest of specialists and consumers home and abroad. On April, 2003 A.V. Skalny opened the first chair of nutritiology and bioelementology in Russia and became its leader. From September, 2003 Bioelementology Institute, the first in the world, being founded by A.V. Skalny under support of Orenburg State University rectorate and RUSTEM, began its activity.

Internal Medicine (General Medicine)

Farid Menaa is an inter- and multi-disciplinar professional (director, professor, researcher and entrepreneur) with increasing international recognition. His strong background is mainly related to medecine, biology, pharmaceutical sciences, biochemistry, biophysics and genetics. Dr. Menaa has studied and worked for/with several reputed institutions worldwide, including Sorbonne (Paris, France), CNRS (France), INSERM (France), CEA (Ministry of Defence, France), SKCC/sanford-Burnham Medical Research Institute (USA), Schools of Medecine of Paris (France), Wuerzburg (Germany) and Campinas (Unicamp, Brazil). Among other responsibilities he carried out, Dr. Menaa has been, for several years, the R&D director of Fluorotronics, Inc. San Diego, CA, USA, a premier company specialized in fluorine chemistry and nanotechnology. Dr. Menaa was also a principal investigator in projects related to Oncology, Dermatology, Stem Cells, Genetics and Hematology. Dr. Menaa is currently an international consulting expert in healthcare and biosystems for a number of organizations and serves as an editorial board member for a large number of esteemed journals in medecine, sciences and business. Dr. Menaa holds dozen of peer-reviewed manuscripts and is a respected member of prestigious scientific/medical organizations and meetings where he is often invited as a chairman.

Medicine; Genetics; Fluorine Chemistry; Nanotechnology; Biophysics; Biochemistry

Acupuncture therapist Serving in holy city ,amritsar ,india , from last 16 years at guru kirpa acupuncture and holistic care center . Spent almost 7 years in the professional study of acupuncture at ludhiana ,kolkata ,coimbatore and canada. Attended 15 national and international acupuncture conferences , in punjab , tamil nadu ,delhi , kolkata , edmonton ( canada ) , lahore ( pakistan ), philadelphia ( u.s.a. ), china . And presented acupuncture papers in 9 conferences out of them . 1.Vice chairman – the alliance of research & development traditional medicines , fudan university ,china. 2.Vice president- acupuncture science association , punjab unit , india . 3.Member - tamilnadu acupuncture council , tamil nadu , india . 4.Member - pakistan acupuncture council , pakistan

Acupuncture therapist

Andreas Scherer is the Project Director for Institute for Molecular Medicine Finland (FIMM)and previously he was a founder and CEO of Spheromics, a company focused on consultancy in biomarker development, as well as analysis and interpretation of complex biomedical datasets. Dr Scherer is a molecular and computational biologist with long experience in gene expression profiling and biomarker development and qualification. Before founding Spheromics in 2007, Dr Scherer worked in various positions for Novartis in Basel, Switzerland. In 2011 he accepted the position Bioinformatics Manager at the Australian Genome Research Facility (AGRF) in Melbourne, AU, from where he returned to Finland in 2013. Dr Scherer is author and co-author of a number of articles in peer-reviewed journals, book chapters, and editor of a book about unwanted variation in microarray datasets. He is advisory board member of the journal “OA Bioinformatics”.

Bioethics, Genomics, Biomarkers

Candida Fratazzi has worked in biomedical research for over 25 years. Prior to her full commitment to Boston Biotech Clinical Research, LLC, she served as Vice President of Clinical Research at MediVector, Inc. Dr. Fratazzi has also held management positions at Johnson & Johnson Pharmaceuticals, Altus Pharmaceuticals Inc., Shire HGT, and Vitex Inc. and Wyeth Pharmaceuticals. During her carrier, Dr. Fratazzi developed clinical strategies and plan developments for many drug candidates, presented in INDs and end-of-phase2 briefing documents. Furthermore, Dr. Fratazzi devoted a special attention to drug safety and risk management recognizing its critical value in the contest of clinical development. Her work resulted in the market approval of Tigecycline® IV (Wyeth), Velaglucerase alpha® (Shire), Replagal® in Canada, and submission of Lipoprotamase (Alnara).She is also chairman of Women in Bio of Greater Boston.

Dr. Andreas Scherer is CEO of Golden Helix. The company has been delivering industry leading bioinformatics solutions for the advancement of life science research and translational medicine for over a decade. Its innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from microarrays and next-generation sequencing. With its solutions, hundreds of the world’s top pharmaceutical, biotech, and academic research organizations are able to harness the full potential of genomics to identify the cause of disease, improve the efficacy and safety of drugs, develop genomic diagnostics, and advance the quest for personalized medicine. Golden Helix products and services have been cited in over 800 peer-reviewed publications. He is also Managing Partner of Salto Partners, a management consulting firm headquartered in the DC metro area. He has extensive experience successfully managing growth as well as orchestrating complex turnaround situations. His company, Salto Partners, advises on business strategy, financing, sales and operations. Clients are operating in the high tech and life sciences space. Dr. Scherer holds a PhD in computer science from the University of Hagen, Germany, and a Master of Computer Science from the University of Dortmund, Germany. He is author and co- author of over 20 international publications and has written books on project management, the Internet, and artificial intelligence. His latest book, “Be Fast Or Be Gone”, is a prizewinner in the 2012 Eric Hoffer Book Awards competition, and has been named a finalist in the 2012 Next Generation Indie Book Awards! He is married and the proud father of one son.

Precision Medicine

Howard Moskowitz, Harvard PhD in experimental psychology (1969) is founding partner and chief scientific officer of Mind Genomics Advisors. He has published extensively in many fields, using the science of Mind Genomics, which he invented more than 30 years ago. After a distinguished dual career in science and business, he changed course, creating an institute to help younger professionals as well as students and business, benefit from the application of Mind Genomics to practical problems in society, including commerce, health, education, and socal issues. Along with hundreds of scientific papers, he has written/edited 27 published books, with an additional 15 books finished but not yet published. His ‘oeuvre’ of work using Mind Genomics is available for download to interested parties at https://www.dropbox.com/sh/vlyiqp6p5eom0m1/AAC1WRPuHOGpax6TLq-md824a?dl=0

Mind Genomics

Sergey Suchkov, MD, PhD was born in 11.01.1957, a researcher-immunologist, a clinician, graduated from Astrakhan State Medical University, Russia, in 1980.Suchkov has been trained at the Institute for Medical Enzymology, The USSR Academy of Medical Sciences,National Center for Immunology (Russia), NIH, Bethesda, USA) and British Society for Immunology to cover 4 British university facilities. Since 2005, Dr Suchkov has been working as Faculty Professor of I.M. Sechenov First Moscow State Medical University and Of A.I.Evdokimov Moscow State Medical & Dental University. From 2007, Suchkov is the First Vice-President and Dean of the School of PPPM Politics and Management of the University of World Politics and Law. In 1991-1995, Dr Suchkov was a Scientific Secretary-in-Chief of the Editorial Board of the International Journal“Biomedical Science” (Russian Academy of Sciences and Royal Society of Chemistry, UK) and The International Publishing Bureau at the Presidium of the Russian Academy of Sciences. In 1995-2005, Suchkov was a Director of the Russian-American Program in Immunology of the Eye Diseases.Dr Suchkov is a member of EPMA (European Association of Predictive, Preventive and Personalized Medicine,Brussels-Bonn), a member of the NY Academy of Sciences, a member of the Editorial Boards for Open Journal of Immunology and others. Dr Suchkov is known as an author of the Concept of post-infectious clinical and immunological syndrome, co-author of a concept of abzymes and their impact into the pathogenesis of autuimmunity conditions, and as one of the pioneers in promoting the Concept of PPPM into a practical branch of health services

Predictive, Preventive and Personalized Medicine,Immunology, Medicine, Pathology

Dr. Sergey Zhuplatov is a Medical Director of the Metabolic Strategy and Development of AstraZeneca LP. Fort Washington, PA. He was graduated as MD at the Izhevsk State Medical Academy in Russia before finishing his fellowship in Internal Medicine/Endocrinology at Moscow Academy of Post diploma Education and Moscow Medical Institute of Transplantology in 1986. He accepted tenure and leading clinical consultant position in Endocrinology/Cardiology clinic at his Alma Mater ISMA. At this time, he started his Ph.D. dissertation in Cardiology with prevention of progressive CV events in Diabetes Mellitus Patients as the main topic, which was perfectly defended at Ural State Medical Academy on 1991. Dr. Zhuplatov has been working as an Assistant Professor and practicing physician till his emigration to the USA in 2002 as an exceptional ability person visa waiver. Before that he worked 2 years as a Medical Scientific Consultant for Merck S&D Co., and also as a Chief Medical Officer in Private Medical Clinic for 2 years. He published different works in Internal Medicine, Lipidology, Endocrinology, and Cardiology. He continued his scientific work in University of Utah Medical School till his merge to Pharmaceutical Industry in 2008. Since then he is working in Cardio/Metabolic area of Medical Affairs and Clinical Development of Bristol-Meyers Squibb and AstraZeneca Co. He currently resides in Bucks County PA with his wife Irina, Industrial Psychology Ph.D. They both like fine arts, travel, and reading. His two sons are graduate students in Economy and Medicine.

Diabetology,Lipids,Ischemic Heart Disease, Microcirculation,Echocardiography,Obesity.

Dr. Luigi Maselli received the Distinguished Doctor Award at San Raffaele University of Rome in honor of his significant contribution to Lifestyle Medicine in Italy. He is a neuroimmunologist with a PhD in Neurosciences and works as a Research Fellow at Sapienza University of Rome – School of Medicine and Dentistry and as a Visiting Fellow at Gabriele d’Annunzio University of Chieti-Pescara – School of Health Sciences. Dr. Maselli is the founding President of the Italian Lifestyle Medicine Association (ILMA). He is active in patient care, research, speaking, teaching and writing, and wrote the first Italian book on Lifestyle Medicine. After establishing his connection with the Institute of Lifestyle Medicine at Harvard Medical School, where he fell in love with Lifestyle Medicine, he established Lifestyle Medicine programs in several Italian universities. His overwhelming enthusiasm for life and propensity for helping others reflect the values that make Lifestyle Medicine unique- for the treatment and prevention of lifestyle-related chronic diseases.

Internal Medicine

Candida Fratazzi has worked in biomedical research for over 25 years. Prior to her full commitment to Boston Biotech Clinical Research, LLC, she served as Vice President of Clinical Research at MediVector, Inc. Dr. Fratazzi has also held management positions at Johnson & Johnson Pharmaceuticals, Altus Pharmaceuticals Inc., Shire HGT, and Vitex Inc. and Wyeth Pharmaceuticals. During her carrier, Dr. Fratazzi developed clinical strategies and plan developments for many drug candidates, presented in INDs and end-of-phase2 briefing documents. Furthermore, Dr. Fratazzi devoted a special attention to drug safety and risk management recognizing its critical value in the contest of clinical development. Her work resulted in the market approval of Tigecycline® IV (Wyeth), Velaglucerase alpha® (Shire), Replagal® in Canada, and submission of Lipoprotamase (Alnara).She is also chairman of Women in Bio of Greater Boston.

Vincent S. Gallicchio has 42 years experience in academic medicine and research covering experimental hematology, immunology, and developmental therapeutics for human diseases such as AIDS and cancer. He has earned national and international respect and recognition for his efforts. In a first time study reporting on academic scholarly productivity in the Journal of Clinical Laboratory Science, Gallicchio was rated the number one academic biomedical laboratory science researcher in the United States. In addition to his passion for research, Gallicchio is equally passionate to teach, mentor and advise students. He has mentored many doctoral and post-doctoral students, dozens of master’s level students and hundreds of undergraduate students both foreign and domestic, many of whom are now esteemed researchers themselves at institutions such as: Oxford University, Eastern Kentucky University, University of Cincinnati, University of Florida, University of Kentucky, University of Limpopo (South Africa), Jewish and Mercy Hospitals in Cincinnati and major pharmaceutical companies such as Procter & Gamble and Johnson & Johnson. As a board certified medical laboratory scientist by the American Society of Clinical Pathology (ASCP), Gallicchio also serves as the Clinical Laboratory Director of the Lab Tree Clinical Biochemical Research Laboratory in Greenville, SC. He also serves as a consultant to Minerals Resources International, Inc on matters related to the health benefits of trace elements; and is a consulting Vice-President of Technology Development for Conversion Laboratories, LLC, and West Columbia, SC. He has served on the faculty and academic staff at the Yale University School of Medicine, the University of Kentucky Medical Center, the University of Central Lancashire (England) and the University of Wolver hampton (England). He has served as President of Alpha Eta Honor Society, the International Society for Lithium Research, International Federation of Biomedical Laboratory Science and currently serves as Vice President of the Educational and Research Centers in Trace Elements program operated under the auspice of UNESCO.

Personalized Medicine, cell science, Trace elemts, biology, Biomedical Laboratory

Gillie Gabay is a systems science expert. Ms. Gabay is a systemic organizational consultant who leads changes that aim at creating an optimal fit between business strategies and organizational strategies. She studies health psychology, at the individual, group and system level researching behavioral processes in health, illness and healthcare. Ms. Gabay promotes a systemic integrated approach where multiple views are accounted for: The view of the health system, the view of the patient and the view of the clinician. She is a senior lecturer at the Organizational Consulting Graduate Program at the College of Management in Israel

Mind Genomics

Roukos DH, Ioannina University, Greece. Dimitrios Roukos, MD (Athens University, Greece), PhD (J.W.Goethe University, Frankfurt a.M., Germany), has moved his scientific interest after 25 years of reductionist medicine to network biology-based systems medicine. Assessing the clinical limitations of current traditional medicine to cure in the future incurable diseases such as cancer, has focused over the last 5 years on human cancer genome both structural variation and functional heterogeneity. His emerging goal is to understand how inherited and somatic mutations, epigenome, transcriptome and interactome abnormalities change chromatin dynamic states and gene expression. Emerging evidence suggests that this gene dysfunction and deregulation of cell signalling pathways drive tumorigenesis and metastasis. His ultimate goal is to approach next-generation anticancer drugs and biomarkers to future achievement of personalized medicine and network biology-based managment of cancer.Publication metrics: > 200 papers with ~ 5,000 citations (h=55) in PubMed, ISI, Scopus and current editor of two eBooks on personalized management of cancer and cancer genome heterogeneity-based treatment of cancer. Currently is key evaluator in European Commission (FP7 Systems Medicine area) and French National Research Agency (22 billion euros) participating in experts panel meeting in Brussels and Paris (end 2011) for the selection of best projects. He is leader of Translational Research in European Union Network of Excellence (EUNE) for gastric cancer and Personalized Cancer Genomic Medicine, Biobank in Ioannina University (Greece). He has been invited speaker and consensus member in multiple International Cancer Meetings. He serves as Editor-in-Chief, Associate Editor and Editorial board member in 20 influential journals.

Assessing limitations of conventional reductionist medicine, he have shifted to multi-scale genes, proteins, molecules, DNA, and RNA interactions in physical and functional networks. Revolutionary NGS technologies provide mow sequencing of DNA (whole genome, exome), transcriptome (RNA-seq, Chip-seq), epigenome (BS-seq) and also along with novel techniques (living cells imaging and computational models) also deeper insights into the grand challenge of interactome (multidimensional spatiotemporal protein-protein interactions). Integrating all these experimental data (omics, living-cells imaging, 3D-genome resolution and intra- and inter-cellular differentiation mapping) and large-scale clinical data into computational models, deep understanding of a personal genome code-lifestyle interactions network is beginning to be shaped. The perspectives of future medicine based on clinical genome and systems science are now rationally excellent for revolutionizing healthcare.

Anatoly Victorovich Skalny was born on the 12th of April, 1962 in Ivano-Frankovsk-City (Ukrain). Graduated school in Olyka village of Volynskaya oblast and medical faculty of Ivano-Frankovsk Medicine State Institute (1985) with honours. Began to carry aout scientific researches from 1979 in a student scientific society under the leadership of professor G.A. Babenko, a leading specialist in medicine elementology in Soviet Union. Ph.D. in Medicine (from 1990). Member of Council on trace elements in agriculture, biology and medicine in AS USSR and RAS (from 1987), Executive Committee of Moscow department of physicians-assistants' Society (from 1989), Boards in ecology and natural recources, science, culture and public health Political Consulting Council under the President of Russian Federation (from 1997), Member of advisory committee in ecology at Moscow City Parliament, co-founder of public movement "Healthy City - health of moscovites" (from 1998). In 1985–1991 worked as a research assistant, Junior Researcher and Researcher in department of restoration treatment of children with cerebral paralysis of Research Institute of common and justice psychiatry by V.P.Serbsky of HM USSR, department of alcoholism genetics in State Scientific Center of narcology of HM USSR. In 1988 he founded scientific-medical center "Element" that is the base to carry out researches of biosubstrates elemental content for medicine purposes during 11 years (for population, health and sanitary-hygienic organizations), scientific institutes such as Research Institute of pediatrics of RAMS, Center for perinatology, obstetrics and gynaecology of HM RF, Navy Institute of Hygiene of HM RF, colleges of medicine of Moscow, Ivanovo, Irkutsk, N.Novgorod and other cities. Center for Biotic Medicine, - autonomous non-profit organization (CBM), - was founded by A.V.Skalny in 1995 that is the unique scientific-methodical Center for problems of applied medicine elementology in RF and UIS. On the 19 of January, 2001 "Russian Society of Medicine Elementology" (RUSTEM) was founded to provide the strongest evolution of trace elements paradigm. During the period from 1982 about 200 scientific articles and thesis' were published by A.V.Skalny in special issues in Russia and abroad as well as manuals and mini-monographs in problems of practical medicine elementology. A.V. Skalny with co-authors registered 3 certificates of authorship and 3 patents of RF and Ukrain in the branch of producing new biologically active compounds of trace elements (Se, Zn) to treat and make prophylaxis of human diseases, methods of treatments of zinc deficiency states, alcohol coma and schysophrenia. To date new line in medicine and ecology, - medicine elementology, - is established by A.V. Skalny in Russia and UIS and developed successfully that studies peculiarities of human organism elemental composition in different functional states and disorders and the ways to increase organism adaptative functions with the help of trace elements metabolism correction. In SMC "Element" and CBM more than 20 Ph.D.'s and 5 D.Sc.' in medicine and biology were trained who develop different applied aspects of medicine elementology in branches of perinatology, endocrinology, urology, nephrology, labour medicine, nutrition hygiene, narcology in leaders clinics of Russia, Ukrain, Kazakhstan, Uzbekistan. In 1998-1999 production of new generation of effective major and trace elements' preparations (compounds with aspartic, spirulina) was organized under the methodic management of organizations headed by A.V. Skalny that awoke interest of specialists and consumers home and abroad. On April, 2003 A.V. Skalny opened the first chair of nutritiology and bioelementology in Russia and became its leader. From September, 2003 Bioelementology Institute, the first in the world, being founded by A.V. Skalny under support of Orenburg State University rectorate and RUSTEM, began its activity.

Internal Medicine (General Medicine)

Farid Menaa is an inter- and multi-disciplinar professional (director, professor, researcher and entrepreneur) with increasing international recognition. His strong background is mainly related to medecine, biology, pharmaceutical sciences, biochemistry, biophysics and genetics. Dr. Menaa has studied and worked for/with several reputed institutions worldwide, including Sorbonne (Paris, France), CNRS (France), INSERM (France), CEA (Ministry of Defence, France), SKCC/sanford-Burnham Medical Research Institute (USA), Schools of Medecine of Paris (France), Wuerzburg (Germany) and Campinas (Unicamp, Brazil). Among other responsibilities he carried out, Dr. Menaa has been, for several years, the R&D director of Fluorotronics, Inc. San Diego, CA, USA, a premier company specialized in fluorine chemistry and nanotechnology. Dr. Menaa was also a principal investigator in projects related to Oncology, Dermatology, Stem Cells, Genetics and Hematology. Dr. Menaa is currently an international consulting expert in healthcare and biosystems for a number of organizations and serves as an editorial board member for a large number of esteemed journals in medecine, sciences and business. Dr. Menaa holds dozen of peer-reviewed manuscripts and is a respected member of prestigious scientific/medical organizations and meetings where he is often invited as a chairman.

Medicine; Genetics; Fluorine Chemistry; Nanotechnology; Biophysics; Biochemistry

Deirdre Kelly Ph.D. career spans both industry and academia where she has worked with both start-up biotech and multinational pharmaceutical companies. Dr Kelly holds a PhD (Medicine, Immunology) from the Royal College of Surgeons in Ireland, a MSc Biotechnology from the National University of Ireland, Galway, and a B.A.(Mod) Biochemistry from Trinity College, Dublin. Dr Kelly founded Kelly Scientific which is a trusted premier provider of cutting edge niche market information within the pharma, biotech and healthcare industries. Personalized medicine, targeted therapeutics, companion diagnostics and immunotherapeutics are key areas that we have significant market expertize in. We are proud to count Fortune 500 companies as many of our repeat corporate clients. Kelly Scientific provides high quality comprehensive business reports for the Pharma/Biotech industry which are updated regularly. We have scientific and business expertise in a number of therapeutic and diagnostic areas including personalized medicine, transdermal and targeted drug delivery, immunotherapy, anti-infectives, respiratory and gastrointestinal disease, genetics, pharmacogenomics, vaccines, biomarkers, biosimilars, inflammation, oncology and diabetes. We are also constantly tracking the USA, European, Russian, Chinese, Indian, Japanese and African Pharma and Biotech markets.

Personalized medicine

Adrian Llerena is the Director of the Clinical Research Center in the University Hospital Infanta Cristina en Badajoz Spain. He is also Professor of Pharmacology and Clinical Pharmacology in two Medical Schools in the University of Extremadura Spain and part time in the University of Beira Interior, Portugal. He earned his PhD at University of Extremadura in 1988 and between 1989 to 1993 did his post doc at Karolinska Institute Sweden focusing on Clinical Pharmacogenetics of antidepressant and antipsychotic drugs. His teaching experience is of more than 20 years in Spain and of about 9 years in Portugal. He has supervised more than 10 PhD thesis

Pharmacology, Personalized Medicine